CD4 and neoplasm: This immunomodulatory activity was also demonstrated in vivo, since the administration of PTSO-pretreated hPBMCs led to an increase in the tumor infiltration of CD4+ T lymphocytes and NK cells, which was associated with a reduction in CD14+ monocytic cells and the downregulation of key immunosuppressive genes, as previously discussed.